Trading Concept
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Trading Concept
No Result
View All Result
Home Trading News

Cramer’s Investing Club: We are nibbling on this drug stock amid the broad market sell-off

by
December 3, 2021
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Here are Friday’s biggest analyst calls of the day: Apple, FedEx, Coinbase, Honeywell, Micron & more

Chinese automaker Nio reports record EV sales in June — but both XPeng and Li Auto did even better

David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

(This article was sent first to members of the CNBC Investing Club with Jim Cramer. To get the real-time updates in your inbox, subscribe here.)

Shortly before the closing bell, we will be buying 25 shares of Eli Lilly (LLY) at roughly $243.81. Following the trade, the Charitable Trust will own 400 shares of Eli Lilly. This buy will increase Eli Lilly’s weight in the portfolio from about 2.28% to 2.43%.

After avoiding the temptation of paying up for stocks yesterday, we will be making one small buy Friday afternoon because we think you have to hold your nose and pick something to nibble on when the broader market is getting hit as hard as it is today. We are going with Eli Lilly today as we look at shares now down roughly 11% from its 52-week high as an opportunity to scale deeper into this relatively newer position.

Loading chart…

We think Eli Lilly is one of the best-run companies in the pharmaceutical industry with its diabetes-focused portfolio that consistently delivers growth without any major loss of exclusivity risk. Eli Lilly also has a strong track record of expanding margins.

But what excites us most about this story is the company’s pipeline. More specifically, Eli Lilly is developing two assets that CEO David Ricks has previously called “two of the most valuable projects we’ve ever worked on and maybe the most valuable projects in the industry right now.”

The two projects Ricks referenced are donanemab as a treatment for Alzheimer’s and tirzepatide in type 2 diabetes and obesity. We think both drugs will be approved by the FDA next year and represent massive long-term opportunities that will support industry-leading growth for years to come.

Back on November 18th in their coverage initiation of Eli Lilly, analysts at BMO Capital called donanemab a potential $10 billion opportunity if access hurdles can be overcome. And in an October research note from JPMorgan, the analysts estimated tirzepatide could be a $10 billion-plus opportunity in type 2 diabetes with potentially multi-billions more in obesity.

The CNBC Investing Club is now the official home to my Charitable Trust. It’s the place where you can see every move we make for the portfolio and get my market insight before anyone else. The Charitable Trust and my writings are no longer affiliated with Action Alerts Plus in any way.

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Typically, Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If the trade alert is sent pre-market, Jim waits 5 minutes after the market opens before executing the trade. If the trade alert is issued with less than 45 minutes in the trading day, Jim executes the trade 5 minutes before the market closes. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. See here for the investing disclaimer.

(Jim Cramer’s Charitable Trust is long LLY.)

ShareTweetPin

Related Posts

Here are Friday’s biggest analyst calls of the day: Apple, FedEx, Coinbase, Honeywell, Micron & more

by
July 1, 2022
0

Here are Wall Street's biggest calls on Friday: Berenberg downgrades FedEx to hold from buy Berenberg said FedEx is "too...

Chinese automaker Nio reports record EV sales in June — but both XPeng and Li Auto did even better

by
July 1, 2022
0

In this article NIO Nio's ES7 sports utility vehicle adds another competitor to Tesla's Model X and Model Y in...

Warren Buffett says these are the best stocks to own when inflation spikes — with consumer prices still raging, it’s time to follow his lead

by
July 1, 2022
0

Motley Fool Why Amazon, Apple, and Nvidia Are Falling Today Shares of Amazon (NASDAQ: AMZN), Apple (NASDAQ: AAPL), and Nvidia...

Energy stocks are the best bet in the market right now, says JPMorgan

by
July 1, 2022
0

JPMorgan is once again pounding the table on energy stocks . The sector has been JPMorgan's highest-conviction overweight since late...

5 things to know before the stock market opens Friday

by
July 1, 2022
0

Here are the most important news items that investors need to start their trading day: 1. Second half begins Traders...

Next Post

DocuSign shares fall 40%, CEO said he is buying $5 million worth of more stock

DraftKings stock price target cut nearly 30% at Benchmark as valuation is ‘rationalized’

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • WHO says Covid vaccine booster programs will prolong pandemic

    0 shares
    Share 0 Tweet 0
  • Spin or Split? AT&T Has a Big Decision to Make on Discovery Stake.

    0 shares
    Share 0 Tweet 0
  • Here’s how Carl Icahn is positioning for a possible recession in America

    0 shares
    Share 0 Tweet 0
  • Some lawmakers and their families are betting thousands of dollars on crypto

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by tradingconcept.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.tradingconcept.net